BCMA/CD3 BsAb Therapy for POEMS Syndrome
ConditionPOEMS Syndrome
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-78
SponsorInstitute of Hematology & Blood Diseases Hospital, China
About this trial
This is a prospective, single-arm, investigator-initiated clinical trial evaluating the safety and efficacy of a BCMA/CD3 bispecific antibody (CM336) in patients with POEMS syndrome.
Eligibility criteria
Qualifiers
Age ≥ 18 years.
Diagnosed with POEMS syndrome according to the 2025 Chinese Expert Consensus.
Deemed suitable for BCMA/CD3 bispecific antibody therapy by the investigator.
ECOG performance status 0-2.
Disqualifiers
Chronic inflammatory demyelinating polyneuropathy (CIDP),
MGUS, multiple myeloma, amyloidosis, or other plasma cell disorders not meeting POEMS diagnostic criteria.
Immunosuppressants used for autoimmune neuropathy;
Bisphosphonates used for bone disease;
Trial design
Treatments tested in this trial
- CM336 (BCMA/CD3 bispecific antibody)
Treatment groups
10 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov